The MHRA has approved depemokimab as an add-on treatment for severe asthma and chronic rhinosinusitis with nasal polyps.

UK's health regulator on Monday approved GSK's twice-yearly drug for use as an add-on treatment for asthma in patients aged ...

Regulators in the UK and US are the first to approve GSK's Exdensur, a long-acting, twice-yearly IL-5 inhibitor for severe ...

GSK plc announced the marketing authorisation of Exdensur (depemokimab) by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA). In the UK, Exdensur is now approved in two indications: ...

A pharmacist has shared the key signs of flu to spot as a new strain has spread through the UK. In recent weeks the H3N2 ...

According to one pharmacist, flu cases have 'picked up a little earlier and a little faster than expected' this year ...

Among seven new medicines recommended for approval by the EMA's human medicine advisory committee at its latest meeting is ...

As with any medicine, the MHRA will keep the safety and effectiveness of depemokimab under close review. The Medicines and Healthcare products ...

The symptoms and severity of H3N2 illness have been similar to seasonal flu, including fever, cough, runny nose, and possibly ...

Monthly monoclonal antibody injection tezepelumab is so effective in patients with severe asthma, half are able to stop daily steroid tablets.

Latest figures from the UK Health Security Agency (UKHSA) show that during the week ending December 7, flu cases climbed, ...

PEOPLE are being warned to “avoid hospitals” if they have flu symptoms to protect vulnerable patients – as the UK braces for ...